Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 217

Sort by

Sort Order Select

Journal Articles

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

Andy Itsara, Victoria M. Rogness, Laura Samples, Constance M. Yuan, Hao-Wei Wang, Inhye E. Ahn, Mohammed Z.H. Farooqui, Xin Tian, Clare Sun, Emily Tomasulo, Susan Soto, Jeanine Superata, Larisa Bezkorovaynaya, Thomas E. Hughes, Pia K. Nierman, Adrian Wiestner

Blood blood.2025029971.

https://doi.org/10.1182/blood.2025029971

Published: 2025

Includes: Supplemental data

Journal Articles

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study

Andrew L. Feldman, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Naoki Oishi, Guangzhen Hu, Pedro Farinha, Catalina Amador, Elías Campo, Wing C. Chan, James R. Cook, Jan Delabie, Kai Fu, Timothy C Greiner, Laura K Hilton, Giorgio GA Inghirami, Javeed Iqbal, Elaine S Jaffe, Ryan Morin, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Philipp W Raess, Andreas Rosenwald, Kerry J. Savage, Graham W. Slack, Susan L. Slager, Joo Y Song, George Wright, Hao-Wei Wang, Yu Zeng, Tadashi Yoshino, Xiaojun Wu, Ryan A Wilcox, xueju wang, Min Shi, Akira Satou, Anamarija M Perry, Roberto Nicolas Miranda, L.Jeffrey Jeffrey Medeiros, Matthew J Maurer, Eric Mou, Young Hyeh Ko, Kennosuke Karube, Brad S Kahl, Liuyan Jiang, David L Jaye, Alejandro Gru, Laurence L de Leval, Weina Chen, Jennifer R. Chapman, James R Cerhan, Carlos Barrionuevo, Stephen M. Ansell, Ahmed Aljudi

Blood blood.2024027700.

https://doi.org/10.1182/blood.2024027700

Published: 2025

Includes: Supplemental data

Journal Articles

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood (2025) 146 (21): 2544–2560.

https://doi.org/10.1182/blood.2024026919

Published: 2025

Includes: Supplemental data

Journal Articles

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Chong Wei, Wei Zhang, Dao-Bin Zhou, Jian Li, Yan Zhang, Kaini Shen, Wei Wang, Zi Wang, Danqing Zhao, Jing Ruan, Huacong Cai, Yueying Mao

Blood (2025) 146 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2025-6322

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations

Lingxu Jiang, Li Ye, Xin Huang, Xinping Zhou, Wei Wang, Lu Wang, Yudi Zhang, Jie Sun, Hongyan Tong

Blood (2025) 146 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2025-3833

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes

Wei Wang, Yingwan Luo, Wei Lang, Wenbin Yang, Hongyan Tong

Blood (2025) 146 (Supplement 1): 5617.

https://doi.org/10.1182/blood-2025-5617

Published: 2025

Journal Articles

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood (2025) 146 (Supplement 1): 927.

https://doi.org/10.1182/blood-2025-927

Published: 2025

Journal Articles

CRLF2-rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: A possible link?

Flavia Mesquita Gava, Bonnie Yates, Grace Li, Chelsea O'Koren, Biplov Adhikari, Haneen Shalabi, Evrim Turkbey, Constance Yuan, Hao-Wei Wang, Sara Silbert, Nirali Shah

Blood (2025) 146 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2025-5099

Published: 2025

Journal Articles

Genetic analysis and clinical correlations in marginal zone lymphoma

Wei Wang, Hao Cai, Yan Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 1768.

https://doi.org/10.1182/blood-2025-1768

Published: 2025

Journal Articles

Dissecting pirtobrutinib resistance in Mantle Cell Lymphoma through single-cell multi-omics

Fangfang Yan, Yang Liu, Heng-Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Lukas Simon, Michael Wang

Blood (2025) 146 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2025-1765

Published: 2025

Journal Articles

Senescence-prone immune cell subsets expand in the aged environment

Yuki Okamura, Teh-Wei Wang, Makoto Nakanishi

Blood (2025) 146 (Supplement 1): 1225.

https://doi.org/10.1182/blood-2025-1225

Published: 2025

Journal Articles

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang, Baijun Fang, Luqun Wang, Songfu Jiang, Yafei Wang, Heng Mei, Wei Yang, Yanjuan He, Wei Wang, Haichao Zhang, Houguo Wang, Jie Jin, Wenming Chen

Blood (2025) 146 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2025-5822

Published: 2025

Journal Articles

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Wei Wang, Yueying Mao, Jing Ruan, Huacong Cai, Jin Ye, JunLi Chen, Liang Wang, Wenrong Huang, Yan Zhang, Jian Li

Blood (2025) 146 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2025-5383

Published: 2025

Journal Articles

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Chelsea O'Koren, Julie Ma, Bonnie Yates, Hao-Wei Wang, Constance Yuan, Chloe Hoang, Tanvi Verma, David Peske, Ilan Kirsch, Challice Bonifant, Nirali Shah

Blood (2025) 146 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2025-3363

Published: 2025

Journal Articles

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Xiyang Liu, Liqing Kang, Hongfei Gu, Wei Zhang, Hongjia Zhu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2025-3713

Published: 2025

Journal Articles

The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells

Michael Wang, Yang Liu, Qingsong Cai, Lei Nie, Heng-Huan Lee, Fangfang Yan, Yue Fei, Yijing Li, Lin Tan, Philip Lorenzi, Cheng-Tai Yu, Wei Wang

Blood (2025) 146 (Supplement 1): 330.

https://doi.org/10.1182/blood-2025-330

Published: 2025

Journal Articles

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Xiyang Liu, Hongjia Zhu, Wei Zhang, Liqing Kang, Hongfei Gu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Peihua Lu, Lei Yu

Blood (2025) 146 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2025-2382

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

CRLF2-rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: A possible link?

Genetic analysis and clinical correlations in marginal zone lymphoma

Dissecting pirtobrutinib resistance in Mantle Cell Lymphoma through single-cell multi-omics

Senescence-prone immune cell subsets expand in the aged environment

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only